

Unimed Pharmaceuticals Incorporated

[View the current Unimed Pharmaceuticals Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bioporcorporate/10453-Unimed+Pharmaceuticals+Incorporated.html)

(<http://www.bioportfolio.com/bioporcorporate/10453-Unimed+Pharmaceuticals+Incorporated.html>)

Contact Details:

2150 East Lake Cook Road
Buffalo Grove
IL
60089
United States of America

Tel: 708 541 2525
Fax: 708 541 2533
Email:

Unimed Pharmaceuticals Incorporated develops and markets prescription pharmaceutical products. Unimed Pharmaceuticals strategy is to establish a leading position within specialty pharmaceutical markets. Unimed Pharmaceuticals expects to build a diversified portfolio of products in several therapeutic areas including HIV and other infectious diseases, endocrinology, hematology, oncology and urology. Currently, the Unimed Pharmaceuticals promotes three approved drugs for these markets: Marinol(R) (dronabinol), an appetite stimulant and antiemetic drug, Maxaquin(R) (lomefloxacin), a fluoroquinolone anti-infective used in the urology and infectious disease markets, and Anadrol(R)(oxymetholone), an orally active anabolic androgenic steroid used to treat various anemias.

Recent Publications by Unimed Pharmaceuticals Incorporated:



- [Andropause: knowledge and perceptions among the general public and health care professionals.](#)
*BACKGROUND: Andropause, the natural age-related decline in testosterone in...*7th February, 2003
Unimed Pharmaceuticals, Inc., Deerfield, Illinois, USA.- J Gerontol A Biol Sci Med Sci. 2002
Dec;57(12):M793-6.

Press Releases on Unimed Pharmaceuticals Incorporated:

Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients	23rd November, 2009	Cumberland Pharmaceuticals Inc.	NASHVILLE, Tenn., Nov. 23 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced positive new top-line results from a study evaluating the safety and efficacy of
Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009	23rd November, 2009	Lexicon Pharmaceuticals, Inc.	THE WOODLANDS, Texas, Nov. 23 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that top-line data from its Phase 2 clinical study with LX1031 in patients with
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders	23rd November, 2009	Isis Pharmaceuticals, Inc.	CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis Supporters and Shareholders, I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the
Oceanside Pharmaceuticals Announces Launch of Librax(R) AG	23rd November, 2009	Valeant Pharmaceuticals International	ALISO VIEJO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Oceanside Pharmaceuticals, part of Valeant Pharmaceuticals International (NYSE: VRX), today announced that it has now launched chlordiazepoxide
Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference	23rd November, 2009	Sagent Pharmaceuticals, Inc.	SCHAUMBURG, Ill., Nov. 23 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company with a focus on injectable products, today announced that Jeffery M. Yordon,

BioNews Results for Unimed Pharmaceuticals Incorporated



- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)
FinanzNachrichten.de: Nov 16 2009 12:34AM Matching: pharmaceuticals
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)

- Dallas Business Chronicle: Nov 16 2009 3:33AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- Kansas City Business Journal: Nov 16 2009 3:25AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- South Florida Business Journal: Nov 16 2009 3:23AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- Washington Business Journal: Nov 16 2009 1:25AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- St Louis Business Journal: Nov 16 2009 12:45AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- San Jose Business Journal: Nov 16 2009 12:35AM Matching: pharmaceuticals*
- [BioSante Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report](#)
- PR inside: Nov 16 2009 4:03AM Matching: pharmaceuticals*
- [Alnylam Pharmaceuticals Down 19.9% Since SmarTrend's Sell Recommendation](#)
- TradingMarkets: Nov 16 2009 4:21AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- Reuters: Nov 16 2009 12:43AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- Globe Investor: Nov 16 2009 12:36AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- StockHouse USA: Nov 16 2009 12:22AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Resu](#)
- TradingMarkets: Nov 16 2009 12:18AM Matching: pharmaceuticals*
- [Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer](#)
- Stockwatch: Nov 16 2009 12:15AM Matching: pharmaceuticals*
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)
- Pharmacy Choice: Nov 15 2009 2:33PM Matching: pharmaceuticals*

Unimed Pharmaceuticals Incorporated Clinical Trials:



- [A Study of Nitazoxanide in the Treatment of AIDS-Related Diarrhea](#)



Unimed Pharmaceuticals Incorporated Patents:

- 6747058- [Stable composition for inhalation therapy comprising delta-9-tetrahydrocannabinol and semiaqueous solvent therefor](#)
- 6703418- [Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection](#)
- 6503894- [Pharmaceutical composition and method for treating hypogonadism](#)
- 5804592- [Method for improving disturbed behavior and elevating mood in humans](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

